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PERSPECTIVE
A braided cancer river connects tumor 
heterogeneity and precision medicine
James J. Hsieh1* and Emily H. Cheng2,3
Abstract 
With the ever-increasing complexity of tumor heterogeneity (TH) discovered through cancer genome sequencing, it 
is apparent that TH has become the biggest hurdle for precision cancer therapeutics. Through studying the genom-
ics of exceptional responders to targeted therapeutic agents in kidney cancer, we demonstrated parallel convergent 
gene/pathway/capability/function evolution of kidney cancer in the context of TH, which prompted us to propose 
a new cancer evolution model “the braided cancer river model”. Based on this model, we might be able to outsmart 
a given cancer type within an individual patient through simultaneously inhibiting preferred parallel pathways or 
sequential nodes. Thus, the goals of this perspective are to define tumor heterogeneity, discuss tumor evolution, 
introduce braided cancer river model, and improve precision medicine.
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Improving precision has always been a common goal 
of the human race, which in turn drives the continuous 
progresses of all disciplines. Cancer has been a mystery 
in health concerning the origin, the identity, the mani-
festation, the management, and the outcome since its 
existence. With the advent of modern molecular, imag-
ing, and treatment technologies in the latter half of the 
20th century, we began to understand the complexity of 
cancer and are now gearing towards delivering precision 
therapeutics for personalized cancer care in the 21st cen-
tury. Currently, we have surgery and radiation for local-
ized cancer control, and chemotherapeutic, targeted, and 
immunotherapeutic agents for systemic management of 
advanced cancers. With the ever-increasing treatment 
options, we are now in an era of precision cancer medi-
cine that promises maximum specificity and effective-
ness. To discuss how we might improve specificity in 
precision medicine, we will concentrate on issues con-
cerning tumor heterogeneity. We can categorize tumor 
heterogeneity into three levels, i.e. macroscopic, micro-
scopic, and molecular. Macroscopically, factors involved 
are individual cancer patient’s race, gender, age, and the 
organ/tissue origin of contracted cancer; microscopi-
cally, factors are histology and tumor microenvironment; 
and molecularly, factors are genetics and epigenetics 
[1]. Beside these foreseeable layers of complex, several 
contemporary studies opened our eyes to the unprec-
edented scale of intra-tumor heterogeneity (ITH) and 
inter-metastases heterogeneity (IMH) within an individ-
ual patient of a given cancer. Facing this daunting tumor 
heterogeneity, curing cancer with precision therapeutics 
seems infeasible. Yet, we are making significant progress 
in converting metastatic cancer from an acute fetal dis-
ease to a manageable chronic illness, and even in some 
scenarios provide continuous remission without ongoing 
treatment, e.g. kidney cancer [1].
The “natural selection” theory by Charles Darwin stipu-
lated that all organisms arise and develop through small, 
inherited variations that increase the individual’s ability 
to compete, survive, and reproduce. Cancer is a disease 
of the genome. Accordingly, the creation, the increased 
proliferation, the uncontrolled migration, and the ulti-
mate demise of individual cancer cells follow Darwinian 
principles. Cancer cell originates from the same copy 
of DNA as its host and acquires new capability through 
mutations. The drastic, uncontrollable, rapid evolution 
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of cancer cell ends with the demise not only of the host 
but also the renegade cancer cells that are constantly in 
chaos.
Central to the cancer evolution principle is the ability 
of cancer cells to rapidly diversify and compete as “clonal 
evolution of tumor cells” [2], favoring linear evolution in 
creating the fittest clone [3]. With the advent of next gen-
eration sequencing and the insight of tumor heterogene-
ity, the extensive ITH was unveiled by the Gerlinger et al., 
where the authors examined tumor DNA of different 
regions of human clear cell renal cell carcinoma (ccRCC) 
and highlighted branched evolution [4]. Since then, diver-
gent/branched evolution has been demonstrated as a 
common phenomenon in multiple cancer types. The 
complexity of cancer cell spreading between primary and 
metastatic tumors and among metastatic lesions was best 
illustrated by Gundem et  al. [5], where the authors uti-
lized whole genome sequencing to deduce the recurrent 
seeding-colonizing-spreading cycles in prostate cancer. 
They found metastasis-to-metastasis colonization was 
common; metastasis-to-metastasis spread can initiate 
through either de novo monoclonal seeding or simultane-
ous transfer of multiple tumor clones; and multiple colo-
nizing events took place among metastases over time [5].
Both ITH and IMH thrive on diversifying through 
mutations and epigenetic changes, which can be viewed 
as an individual ever-branching cancer tree. The trunk-
branch model concerning ITH and IMH pinpoints the 
strategy for effective cancer control through targeting 
“trunk” lesions [6], explaining the known success of mul-
tiple kinase inhibitors in treating certain human cancers 
bearing truncal activating mutations at respective kinases 
[7]. Another key finding in the Gerlinger et  al. paper is 
that different mutations at the very same genes were 
detected in different regions of the same tumor. This 
observation underscores the notion that upon expansion, 
invasion, and metastasis tumor would do whatever is 
necessary to activate or inactivate “certain” genes through 
convergent evolution in order to increase fitness [8]. This 
data is consistent with the “Hallmarks of Cancer” concept 
proposed by Weinberg et al. [9] where certain biological 
capabilities are acquired during the multistep develop-
ment of human tumors [10, 11]. In other words, conver-
gence on genes, pathways, and capabilities/functions 
confers the ultimate phenotypes in cancer evolution.
For ccRCC, two classes of targeted agents have been 
approved that target VEGF and mTOR pathways [12] 
and collectively improved overall survival of metastatic 
patients [11, 13]. The median progression free survival 
(PFS) for metastatic ccRCC patients receiving mTORC1 
inhibitors is  <6  months. Nevertheless, a small group of 
patients experienced markedly longer survival [14, 15]. 
For example, a median PFS of 28  months was reported 
in an outlier study of five patients with metastatic ccRCC 
[14]. In three of five patients, multi-region analysis 
revealed marked ITH, whereas results revealed pathway 
convergence upon mTOR pathway activation [11, 14]. For 
example, two distinct and spatially separate mutations in 
TSC1 and MTOR, along the PI3 K/AKT/mTOR pathway, 
that activate mTOR kinase through different mechanisms 
were detected in different regions of the same tumor [14]. 
What can we learn from studying targeted therapeutic 
outliers of a given cancer type, which gives rise to seem-
ingly contradictory phenotypes, i.e. diversification in 
mutations and durable benefit on one drug? The recur-
rent theme is parallel/convergent evolution on select sets 
of oncogenic pathways [11, 14, 16]. Importantly, such 
pathway or phenotype convergence takes place within 
and among tumors, and is probably shared by a given 
cancer type in the presence of ITH and IMH [11]. Based 
on these insights on parallel/convergent gene/pathway/
function (capability)/phenotype evolution [11, 14, 16], 
kidney cancer development may be better visualized 
as a braided river with the capacity to diverge and con-
verge rather than an ever-branching tree. The riverhead is 
analogous to the trunk mutation, originating with a ubiq-
uitous driver event. The heterogeneous mutations previ-
ously ascribed to the branches of tree become tributaries 
along the river, which retain the capability to become 
driver mutations and converge with other spatially or 
temporally distinct mutations that affect the same genes 
or components along critical oncogenic or tumor sup-
pressor pathways inherent to a given cancer type [11].
This braided cancer river model illustrates parallel and 
convergent events occurring throughout tumorigenesis. 
Starting from initiating driver mutations, this model 
depicts the stepwise acquisition of different driver muta-
tions (early, intermediate, late and speedy drivers) during 
cancer evolution. Based on this model, one can envision 
how we might be able to outsmart cancer before resist-
ance to targeted agents occur through agents simultane-
ously inhibiting parallel pathways or sequential nodes, 
which could explain the therapeutic benefits of admin-
istering lenvatinib (a VEGF and FGF inhibitor) plus 
everolimus (an mTOR inhibitor) [17] and cabozantinib (a 
VEGF and c-MET inhibitor) [18] in ccRCC patients who 
have failed frontline anti-VEGF therapies and the combi-
nation of bevacizumab (an anti-VEGF-A antibody) and 
everolimus in non-clear cell RCC with papillary features 
[19]. Furthermore, with recent success in cancer therapy 
using immune checkpoint blockade (ICB) antibodies 
[20], one might consider combining these two different 
strategies, namely targeted agents and cancer immu-
notherapies, as the future precision cancer medicine. 
In fact, such approaches are being explored in phase III 
trials.
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In conclusion, with the advent of NGS and the afford-
able cost for sequencing tumors, we can now evaluate 
tumors at base-pair resolution and with the availabil-
ity of large cancer genomics dataset, we should be able 
to better model individual tumor evolution in real time 
with precision. The future of cancer therapeutic is to tar-
get cancer cells at fine resolution, fulfilling the promise 
of precision medicine, which will likely reduces the even-
tual economic and social burdens imposed by cancer as a 
whole.
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